China Medical System Holdings Limited

Symbol: CHSYF




Market price today

  • 4.8874

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 2.28B

    MRK Cap

  • 0.09%

    DIV Yield

China Medical System Holdings Limited (CHSYF) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Kong Lam
Full-time employees:5622
City:North Point
Address:Island Place Tower

China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company's products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. Its products also comprise DanShenTong capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.; XiDaKang, a protein hydrolysate oral solution; YiNuoShu for treating respiratory diseases; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; and Parlodel tablets for the endocrine and neuro system indications. In addition, the company also offers Elcatonin injection for osteoporosis; YinlianQinggan granules for treating acute hepatitis A and chronic hepatitis B; Lamisil tablets for treating fungal infections on skin and hair; and MOVICOL for treating chronic constipation and faecal impaction. In addition, it is involved in the agriculture and livestock activities. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.

General Outlook

In simple terms, China Medical System Holdings Limited has 2451.99 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.774% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.387%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.363%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.184% return, is a testament to China Medical System Holdings Limited's adeptness in optimizing resource deployment. China Medical System Holdings Limited's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.221%. Furthermore, the proficiency of China Medical System Holdings Limited in capital utilization is underscored by a remarkable 0.223% return on capital employed.

Stock Prices

China Medical System Holdings Limited's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $1.6, while its low point bottomed out at $1.6. This variance in figures offers investors a lucid insight into the roller-coaster ride that is China Medical System Holdings Limited's stock market.

Liquidity Ratios

Analyzing CHSYF liquidity ratios reveals its financial health of the firm. The current ratio of 416.46% gauges short-term asset coverage for liabilities. The quick ratio (368.64%) assesses immediate liquidity, while the cash ratio (200.55%) indicates cash reserves.

Current Ratio416.46%
Quick Ratio368.64%
Cash Ratio200.55%

Profitability Ratios

CHSYF profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 42.84% underscores its earnings before tax deductions. The effective tax rate stands at 14.89%, revealing its tax efficiency. The net income per EBT, 84.75%, and the EBT per EBIT, 110.75%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 38.68%, we grasp its operational profitability.

Pretax Profit Margin42.84%
Effective Tax Rate14.89%
Net Income per EBT84.75%
EBT per EBIT110.75%
EBIT per Revenue38.68%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 4.16, it details the span from stock purchase to revenue. The 4 days it takes to settle debts showcases its creditor relations. Meanwhile, a 2 cash conversion cycle and 443.11% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

Days of Sales Outstanding369
Days of Inventory Outstanding107
Operating Cycle189.16
Days of Payables Outstanding42
Cash Conversion Cycle147
Receivables Turnover4.43
Payables Turnover8.60
Inventory Turnover3.42
Fixed Asset Turnover19.67
Asset Turnover0.51

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 0.14, and free cash flow per share, 0.13, depict cash generation on a per-share basis. The cash per share value, 2.48, showcases liquidity position. A payout ratio of 0.03 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.04, offers insight into cash flow relative to sales.

Operating Cash Flow per Share0.14
Free Cash Flow per Share0.13
Cash per Share2.48
Payout Ratio0.03
Operating Cash Flow Sales Ratio0.04
Free Cash Flow to Operating Cash Flow Ratio0.95
Cash Flow Coverage Ratio0.26
Short Term Coverage Ratio0.27
Capital Expenditure Coverage Ratio20.91
Dividend Paid and Capex Coverage Ratio3.39
Dividend Payout Ratio0.05

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 7.19%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.08, we discern the balance between debt and equity financing. The long-term debt to capitalization, 0.16%, and total debt to capitalization, 7.64%, ratios shed light on its capital structure.

Debt Ratio7.19%
Debt Equity Ratio0.08
Long Term Debt to Capitalization0.16%
Total Debt to Capitalization7.64%
Cash Flow to Debt Ratio0.26
Company Equity Multiplier1.15

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 3.73, provides a glimpse into top-line earnings distributed across each share. Net income per share, 1.33, reflects the portion of profit attributed to each share. The book value per share, 5.95, represents the net asset value distributed per share, while the tangible book value per share, 3.96, excludes intangible assets.

Revenue Per Share3.73
Net Income Per Share1.33
Book Value Per Share5.95
Tangible Book Value Per Share3.96
Shareholders Equity Per Share5.95
Interest Debt Per Share0.76
Capex Per Share-0.21

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 9.75%, indicates top-line expansion, while the gross profit growth, 12.63%, reveals profitability trends. EBIT growth, 7.25%, and operating income growth, 7.25%, offer insights into operational profitability progression. The net income growth, 8.01%, showcases bottom-line expansion, and the EPS growth, 9.02%, measures the growth in earnings per share.

Revenue Growth9.75%
Gross Profit Growth12.63%
EBIT Growth7.25%
Operating Income Growth7.25%
Net Income Growth8.01%
EPS Growth9.02%
EPS Diluted Growth9.02%
Weighted Average Shares Growth-0.56%
Weighted Average Shares Diluted Growth-0.56%
Dividends per Share Growth11.13%
Operating Cash Flow Growth42.48%
Free Cash Flow Growth31.15%
10-Year Revenue Growth per Share411.79%
5-Year Revenue Growth per Share73.39%
3-Year Revenue Growth per Share52.28%
10-Year Operating CF Growth per Share702.65%
5-Year Operating CF Growth per Share73.83%
3-Year Operating CF Growth per Share40.56%
10-Year Net Income Growth per Share504.17%
5-Year Net Income Growth per Share97.23%
3-Year Net Income Growth per Share68.01%
10-Year Shareholders Equity Growth per Share413.02%
5-Year Shareholders Equity Growth per Share103.27%
3-Year Shareholders Equity Growth per Share55.67%
10-Year Dividend per Share Growth per Share607.11%
5-Year Dividend per Share Growth per Share111.67%
3-Year Dividend per Share Growth per Share56.79%
Receivables Growth-5.97%
Inventory Growth0.98%
Asset Growth12.31%
Book Value per Share Growth15.04%
Debt Growth5.86%
R&D Expense Growth9.30%
SGA Expenses Growth12.64%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 20,808,423,658.691, captures the company's total value, considering both debt and equity. Income quality, 0.94, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.07, gauges operational efficiency, while the research and development to revenue, 1.37%, highlights investment in innovation. The ratio of intangibles to total assets, 28.26%, indicates the value of non-physical assets, and capex to operating cash flow, -14.77%, measures reinvestment capability.

Enterprise Value20,808,423,658.691
Income Quality0.94
Sales General and Administrative to Revenue0.07
Research and Development to Revenue1.37%
Intangibles to Total Assets28.26%
Capex to Operating Cash Flow-14.77%
Capex to Revenue-5.74%
Capex to Depreciation-231.01%
Stock-Based Compensation to Revenue0.20%
Graham Number13.33
Return on Tangible Assets25.59%
Graham Net Net1.88
Working Capital5,952,273,000
Tangible Asset Value9,719,246,000
Net Current Asset Value5,812,914,000
Average Receivables2,104,430,500
Average Payables161,953,500
Average Inventory474,902,000
Days Sales Outstanding81
Days Payables Outstanding31
Days of Inventory On Hand82

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.03, and the price to book ratio, 1.03, reflect the market's valuation relative to the company's book value. The price to sales ratio, 1.77, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 50.26, and price to operating cash flows, 47.85, gauge market valuation against cash flow metrics.

Price Book Value Ratio1.03
Price to Book Ratio1.03
Price to Sales Ratio1.77
Price Cash Flow Ratio47.85
Enterprise Value Multiple5.16
Price Fair Value1.03
Price to Operating Cash Flow Ratio47.85
Price to Free Cash Flows Ratio50.26
Price to Tangible Book Ratio1.60
Enterprise Value to Sales2.27
Enterprise Value Over EBITDA5.41
EV to Operating Cash Flow5.86
Earnings Yield13.94%
Free Cash Flow Yield12.96%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of China Medical System Holdings Limited (CHSYF) on the PNK in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 4.887 in 2024.

What is the ticker symbol of China Medical System Holdings Limited stock?

The ticker symbol of China Medical System Holdings Limited stock is CHSYF.

What is company IPO date?

IPO date of China Medical System Holdings Limited is 2013-04-05.

What is company current share price?

Current share price is 0.931 USD.

What is stock market cap today?

The market cap of stock today is 2283538287.000.

What is PEG ratio in 2024?

The current 0.000 is 0.000 in 2024.

What is the number of employees in 2024?

In 2024 the company has 5622.